


As we enter the last trading week of the year, low trading volume and a flat outlook dominate the markets. Among the key agenda items for this week are the BIST 100 index's preparation to close the year above the 11,000 level and the U.S. indices approaching their peak.
The period leading up to 2025 saw the AI rally and growth expectations largely priced in. However, it is forecasted that starting in 2026, investors will behave more selectively, focusing on long-term structural stories. In this new environment, not only companies that grow their revenue but also those that maintain profitability and can generate cash flow will stand out.
The evolution of market conditions will attract investors' attention to companies with high operational efficiency and solid financial quality. Companies that can blend growth with financial quality will eliminate the need for external funding and become self-financing. For 2026, the expected growth in earnings per share is projected to be above 25%, and the EBITDA margin is also above the industry average.
The Fear and Greed Index, which evaluates the emotional state of investors, provides important insights about the fluctuations experienced. In the past week, Novo Nordisk shares gained 9.69% following FDA approval, while Oklo shares lost 8.05% due to concerns.
```.png)
Sizlere kesintisiz haber ve analizi en hızlı şekilde ulaştırmak için. Yakında tüm platformlarda...